Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.

ABSTRACT: : In oncology, an increasing number of targeted anticancer agents and immunotherapies are of biological origin. These biological drugs may trigger immune responses that lead to the formation of antidrug antibodies (ADAs). ADAs are directed against immunogenic parts of the drug and may affect efficacy and safety. In other medical fields, such as rheumatology and hematology, the relevance of ADA formation is well established. However, the relevance of ADAs in oncology is just starting to be recognized, and literature on this topic is scarce. In an attempt to fill this gap in the literature, we provide an up-to-date status of ADA formation in oncology. In this focused review, data on ADAs was extracted from 81 clinical trials with biological anticancer agents. We found that most biological an

SUBMITTER: van Brummelen EM 

PROVIDER: S-EPMC5061540 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature